Unmet Needs in the Treatment of Patients With MDS
Amy Dezern, MD, MHS, closes her discussion by emphasizing the need for more treatments in MDS.
Luspatercept as a First-Line Treatment for Patients With Lower-Risk MDS
Dr Amy Dezern discusses the FDA priority review for luspatercept in the first-line setting for MDS and how it may impact patients.
Dose Titration of Luspatercept in Patient With MDS
Amy Dezern, MD, MHS, explains the importance of proper dose titration for luspatercept in the treatment of MDS.
Rationale for Treatment of MDS With Luspatercept
Dr Amy Dezern reviews the mechanism of action of luspatercept and its rationale for use in MDS.
Treating MDS with Erythropoiesis-Stimulating Agents (ESAs)
Amy Dezern, MD, MHS, details her experience with using erythropoiesis stimulating agents for the treatment of MDS in her clinical practice.
The Importance of Early Frontline Treatment Initiation for Patients With MDS
Dr Amy Dezern emphasizes how delayed frontline treatment of MDS can impact overall outcomes for patients with MDS.
Available First-Line Treatment Options for MDS
Amy Dezern, MD, MHS, describes the currently available first-line treatment options for patients with MDS.
Classification and Risk Stratification of MDS
Dr Amy Dezern discusses the criteria for subtype classification and risk stratification in patients with MDS.
Case Presentation: A 70-Year-Old Man with Myelodysplastic Syndrome (MDS) and Low ISSP-R
Amy Dezern, MD, MHS, shares the case of a 70-year-old man with MDS stratified as low-risk using the Revised International Prognostic Scoring System.
2 Clarke Drive Cranbury, NJ 08512